Our results demonstrate that combination therapy with PI3K inhibitors is a promising avenue for future molecular therapy but also warn that thorough studies with high-resolution methods are required to fully resolve complex biochemical signals in heterogeneous cell populations of T-ALL. The gene discussed is PIK3CA; the disease is acute lymphoblastic leukemia.